Attendee search 

Mendor - the new diabetes movement

Mendor is a diabetes technology company with two main products:
1. Mendor Discreet - a globally unique all-in-one integrated glucose meter
2. Mendor Balance - a cloud-based glucose profiling & diabetes management platform for clinics, HCPs & diabetics.

Our key partners include:
Menarini Diagnostics, Merck Serono, Sanofi & Lilly.

Our revenue history:
2011: 0,2M€
2012: 0,6M€
2013 01-07: 3,2M€

Company presentation with some more details:
https://www.dropbox.com/sh/ycp289w4g8wmqwn/0Yj457jnK8/Mendor_Company_Presentation-Aug_2013.pdf

Innokas Medical provides services on product development, manufacturing and life-cycle management for world class medical devices. We are focused on medical devices and have tailored our processes to meet the needed quality and regulatory requirements.

Bone Index Finland Ltd. provides patented, reliable and cost effective solution for the growing need of osteoporosis diagnostics at primary healthcare.

Quality and safety are essential part of our business. Bone Index Finland has ISO 13485 certified Quality System as a medical device manufacturer. Products manufactured by us fulfill the requirements of Medical Device Directive (MDD 93/42/EEC).

It is estimated that over 75% of osteoporotic patients are not diagnosed nor receive treatment for their condition because the diagnostics is done in special healthcare. Our solution to fight this problem, Bindex®, is validated against prevailing gold standard in diagnostics (axial DXA) at special healthcare by using international guidelines. Therefore Bindex® results are comparable to axial DXA.

By using the world’s first pocket size instrument for bone densitometry, Bindex®, the osteoporosis can be diagnosed wherever you want!

Magnasense Technologies Oy

Superior immunoassay performance utilising paramagnetic labels - MagneticImmunoAssay (MIA).

Magnasense has developed a sensitive, simple and elegant system for performing lateral flow immunoassays utilising paramagnetic particles as labels.

Biological materials contain no background magnetism, enabling great sensitivity, while the elimination of chemical, enzymatic and fluorescent reagents simplifies the assay procedure.

The magnetic label interacts directly with the reader’s electronics eliminating the need for light sources and optics.

The above factors provide a uniquely sensitive, robust and inexpensive system.

The system is widely applicable. Quantitative, Near Patient / Point of Care (POC) assays and tests can be rapidly developed with high sensitivity and dynamic ranges of over four decades.
Healthcare applications include cardiac monitoring, e.g. hsCRP and infectious diseases, e.g. viruses.

Outside healthcare, assays can be developed for other applications where rapid results are required, such as veterinary testing, and food and environmental contamination

Applications:
Near Patient Testing, Point of Care Testing, Veterinary Testing, Mould / Mycotoxin testing, Food adulteration, Environmental testing

Optomeditech Oy develops patent pending breakthrough technology in the field of Intravascular Catheters. The technology uses laser light to aid in placement of the IV catheters, making the process easier, faster, safer and more reliable.

The global IV catheter market is roughly a $2B a year market that is growing 10% a year. Over 30% of first attempts to place IV catheters fail today causing significant costs and discomfort for the patients and caretakers alike. The poor placement of IV catheters is the most common cause of complaints in the hospitals. Optomeditech's product OptiVein has the technology to capture a significant portion of the IV catheter market quickly with the advantages it brings.

Optomeditech Oy has confirmed its regulatory pathway for both its CE mark and 510(k) clearance through presubmission consultation with BSI and FDA respectively and is looking to achieve CE mark by the end of Q1 2014 and 510(k) in the summer of 2014. The company is planning on entering the US market during 2015.

The company is currently conducting a clinical trial at the Helsinki University Hospital in Finland and the results have been very good to date. The clinical trial is scheduled to close at the end of August 2013.